Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
Conditions
Keywords
TNO155, spartalizumab, ribociclib, checkpoint inhibitor, SHP2, PD-1, CDK4/6, NSCLC, CRC, HNSCC, KRAS, esophageal SCC, GIST
Brief summary
This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.
Detailed description
Rationale The purpose of this study was to evaluate the safety, tolerability, and preliminary efficacy of the combination of TNO155 with spartalizumab and of TNO155 with ribociclib, and to identify dosing regimens for further study. Data from preclinical models have demonstrated anti-tumor activity for the combinations of TNO155 with spartalizumab and of TNO155 with ribociclib that is superior to the activity observed with each of the drugs as single agents. These data suggest that these combinations may provide clinical benefit to patients with advanced malignancies. Study Design This study was a Phase Ib, multi-center, open-label study with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors to characterize the safety and tolerability TNO155 in combination with spartalizumab and of TNO155 in combination with ribociclib and to identify the MTD and/or recommended regimen (dose and schedule) for each combination. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent. Objectives Primary objective: To characterize the safety and tolerability TNO155 in combination with spartalizumab and of TNO155 in combination with ribociclib, and to identify the MTD and/or recommended regimen (dose and schedule) for each combination. Secondary objectives: * To characterize the pharmacokinetic (PK) profile of TNO155, spartalizumab and ribociclib when administered as a combination of TNO155 plus spartalizumab or of TNO155 plus ribociclib. * To evaluate the preliminary anti-tumor activity of TNO155 in combination with spartalizumab and of TNO155 in combination with ribociclib.
Interventions
DRUGTNO155
Capsule
DRUGSpartalizumab
Concentrate for solution for infusion
DRUGRibociclib
Capsule and tablet
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Age ≥ 18 years. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she is under the age of 20 years. 3. ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1. 4. Dose escalation part: Patients with advanced solid tumors, with evaluable disease as determined by RECIST version 1.1, and fit into one of the following groups: a. For TNO155 plus spartalizumab combination: i. Advanced EGFR WT, ALK WT NSCLC, after progression on or intolerance to platinum-containing combination chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy. ii. Advanced HNSCC or esophageal SCC, after progression on or intolerance to platinum-containing combination chemotherapy. iii. Advanced CRC, after progression on or intolerance to all standard-of-care (SOC) therapy per local guidelines. b. For TNO155 plus ribociclib combination: Advanced solid malignancies with the exception of CRC or GIST, after progression on or intolerance to all SOC therapy per local guidelines. The exclusion of CRC applies only as of Protocol Amendment 4. 5. Dose expansion part: Patients with advanced solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who fit into one of the following groups: a. For TNO155 plus spartalizumab combination: i. Advanced EGFR WT, ALK WT, KRAS G12C NSCLC after progression on or intolerance to platinum-containing combination chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy. ii. Advanced EGFR WT, ALK WT, KRAS WT NSCLC, after progression on or intolerance to platinum-containing combination chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy. iii. Advanced HNSCC, after progression on or intolerance to, platinum-containing combination chemotherapy. b. For TNO155 plus ribociclib combination: i. Advanced EGFR WT, ALK WT, KRAS WT NSCLC, after progression on or intolerance to platinum-containing chemotherapy and anti-PD-1 or anti-PD-L1 therapy ii. Advanced HNSCC, after progression on or intolerance to all SOC per local guidelines 6. Patients with NSCLC whose tumors harbor genomic aberrations for which SOC targeted therapies exist and are locally approved and available must have had progression on or after, or intolerance to, the SOC targeted therapy/therapies as indicated 7. Patients must have a site of disease amenable to biopsy Key
Exclusion criteria
1. Prior treatment with a MAPK pathway inhibitor 2. Clinically significant cardiac disease or risk factors 3. Use of any agent known to prolong the QT interval unless it can be permanently discontinued for the duration of study (see list in Section 6.2.2). 4. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO 5. Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs 6. Symptomatic CNS metastases which are neurologically unstable 7. Insufficient bone marrow function at screening: 1. Absolute Neutrophil Count (ANC) \< 1.5 x 109/L. 2. Hemoglobin \< 9.0 g/dL. 3. Platelets \< 75 x 109/L for TNO155 plus spartalizumab combination; \< 100 x 109/L for TNO155 plus ribociclib combination. 8. Insufficient hepatic or renal function at screening: 1. Serum total bilirubin \> upper limit of normal (ULN) or, for TNO155 plus spartalizumab combination only, if liver metastases are present at baseline, serum total bilirubin \> 1.5 x ULN. An exception for either combination is for patients with Gilbert's syndrome, who are excluded if total bilirubin \> 3.0 x ULN or direct bilirubin \> 1.5 x ULN 2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x ULN for TNO155 plus spartalizumab combination or \> 2.5 x ULN for TNO155 plus ribociclib combination, or \> 5 x ULN for either combination if liver metastases are present. 3. Creatinine clearance \< 60 mL/min (calculated using Cockcroft-Gault equation). 9. Pregnant or breast-feeding (lactating) women. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLT incidence | 1 year | Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part |
| AE and SAE incidence | 3 years | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment |
| Dose interruptions, reductions and dose intensity, by treatment | 3 years | Dose tolerability |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): AUClast | 3 years | AUClast for TNO155, spartalizumab, and ribociclib |
| Pharmacokinetics (PK): AUCtau | 3 years | AUCtau for TNO155, spartalizumab, and ribociclib |
| Efficacy measurements per RECIST v1.1: ORR | 3 years | Overall response rate (ORR) per RECIST v1.1, by treatment |
| Efficacy measurements per RECIST v1.1: DCR | 3 years | Disease control rate (DCR) per RECIST v1.1, by treatment |
| Efficacy measurements per RECIST v1.1: PFS | 3 years | Progression-free survival (PFS) per RECIST v1.1, by treatment |
| Efficacy measurements per iRECIST: PFS | 3 years | Progression-free survival (PFS) per iRECIST for TNO155 in combination with spartalizumab |
| Efficacy measurements per iRECIST: ORR | 3 years | Overall response rate (ORR) per iRECIST for TNO155 in combination with spartalizumab |
| Efficacy measurements per iRECIST: DCR | 3 years | Disease control rate (DCR) per iRECIST for TNO155 in combination with spartalizumab |
| Efficacy measurements per iRECIST: DOR | 3 years | Duration of response (DOR) per iRECIST for TNO155 in combination with spartalizumab |
| Overall Survival | 3 years | Overall survival (OS) by treatment |
| Efficacy measurements per RECIST v1.1: DOR | 3 years | Duration of response (DOR) per RECIST v1.1, by treatment |
| Pharmacokinetics (PK): Cmax | 3 years | Cmax for TNO155, spartalizumab, and ribociclib |
| Pharmacokinetics (PK): Tmax | 3 years | Tmax for TNO155, spartalizumab, and ribociclib |
Countries
Australia, Belgium, China, Germany, Hong Kong, Japan, Singapore, Spain, United States
Outcome results
None listed